Install
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Balancing Disease Control and Safety for Older Adults With IBD
2+ day, 50+ min ago (146+ words) Adam Faye, MD, of NYU Langone Health, New York, New York, shares results from a study evaluating the safety of guselkumab among older populations of patients with immune-mediated inflammatory diseases, such as inflammatory bowel disease (IBD), psoriasis, and psoriatic arthritis....
Arthritis Drug Demonstrates Substantial Hair Regrowth in 1,400 Alopecia Patients
3+ day, 10+ hour ago (426+ words) An arthritis drug of all things was recently found in a study to restore up to 100% of hair in patients with severe alopecia. Around 2% of the world population live with alopecia areata, an autoimmune disorder where the human immune system…...
Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata
3+ day, 19+ hour ago (323+ words) The Clinical Trial Vanguard Nektar to Release 24-Week Off-Treatment Data for Rezpegaldesleukin in Alopecia Areata Nektar Therapeutics went quiet on September 8, 2026, and will stay that way until it releases the 24-week off-treatment follow-up data from its Phase 2b REZOLVE-AA study of…...
QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy — TradingView News
4+ day, 4+ hour ago (75+ words) QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy TradingView QTTB: Phase II results support phase III advancement for a safe, effective alopecia areata therapy Positive phase II data for bempikibart in alopecia areata…...
IBD's Most Persistent Gap and the Potential the Missing Piece: Q&A with Christian Thienel
4+ day, 11+ hour ago (296+ words) Pharmaceutical Executive In 2024, Pharmaceutical Executive reported on a survey that showed a significant number of patients suffering from irritable bowel disease (IBD) struggle to afford proper healthcare According to the results, treatments became unattainable due to barriers such as financial…...
Scientists Discover a Hidden Defect That Could Explain Why IBD Keeps Coming Back
5+ day, 1+ hour ago (434+ words) A hidden molecular defect in inflammatory bowel disease may help explain why flare-ups can return even when patients appear well....
Advancements in Oral Treatments for IBD
5+ day, 11+ hour ago (235+ words) Christian Thienel on the oral IBD mechanisms generating the most excitement — SIK2, oral IL-23, TYK2 — and why multiple could succeed. In 2024, Pharmaceutical Executive reported on a survey that showed a significant number of patients suffering from irritable bowel disease (IBD) struggle to…...
Arthritis medication has been shown to be effective against alopecia, according to a study
5+ day, 11+ hour ago (331+ words) Upadacitinib, an anti-inflammatory drug used to treat arthritis, has been tested as a potential treatment for alopecia areata. An international team of researchers reported the results of two Phase III clinical trials in in a magazine JAMA Dermatology. A total…...
Alopecia Awareness Month: Breaking the stigma around hair loss
5+ day, 17+ hour ago (994+ words) FlySafair evolves its Business Booster into the Travel Booster, a new platform dedicated to South Africa’s tourism economy Vox and CallCabinet turn compliance call recording into a business asset Adams & Adams strengthens Africa-wide IP network as businesses face growing cross-border…...
HCW Biologics Strengthens U.S. Patent Estate for Its Lead Clinical-Stage Immunotherapeutic HCW9302 as Alopecia Areata Treatment
1+ week, 3+ day ago (378+ words) HCW9302 is a best-in-class IL-2-based immunotherapeutic for treatment of autoimmune diseases through expanding and activating regulatory T cells Patent allowance received for use of HCW9302 as treatment for alopecia areata Phase 1 dose-escalating clinical study evaluating HCW9302 as monotherapy in patients with alopecia areata…...